aibioTuHURA Biosciences makes $650,000 draw on Parkview credit line
Tickers HURA
TuHURA reported the draw in an 8-K dated September 17, 2026. Parkview Holdings One LLC is the lender, and cash and cash equivalents were $995,977 at June 30, 2026.
Key facts
- Company
- TuHURA Biosciences, Inc. (NASDAQ: HURA)
- News type
- Debt Financing
- Primary source
- TuHURA Biosciences, Inc. 8-K (2026-09-17)
The September 14 draw
TuHURA Biosciences, Inc. received and borrowed an additional draw of $650,000 under its revolving credit facility on September 14, 2026. The company reported the draw in a Form 8-K dated September 17, 2026, and said it expects to use the funds for general corporate purposes.
The facility comes from a Loan Agreement the company entered into on April 21, 2026 with Parkview Holdings One LLC, as lender. The revolving credit facility matures April 21, 2031, and its maximum loan availability is $50 million. The company filed the Loan Agreement as Exhibit 4.1 to an 8-K filed April 22, 2026. The 8-K describes the Loan Agreement only in summary and refers readers to the full text.
The filing names no placement agent, financial advisor or counsel for the draw. It names Parkview as lender and gives no interest rate, fee or repayment schedule for the draw.
Conditions and conflicts
The filing flags two risks. The company may be unable to meet the conditions for drawing funds, or to stay in compliance with the terms of the loan. It also flags potential conflicts of interest arising from the Loan Agreement with an affiliate of the company's largest stockholder. The 8-K gives no detail on the affiliate's stake or on what the conflicts could involve.
The filing also says funds under the Loan Agreement may not be enough to fund operations and development programs as planned. The company does not state how long a $650,000 draw would sustain its spending.
What TuHURA is developing
TuHURA calls itself a phase 3 clinical stage immuno-oncology company with three technologies. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company began a single randomized, placebo-controlled phase 3 registration trial in June 2025, testing IFx2.0 as an adjunctive therapy to Keytruda in first-line treatment of advanced or metastatic Merkel cell carcinoma, under the FDA's accelerated approval pathway.
The company also holds TBS-2025, a VISTA-inhibiting antibody, through its acquisition of Kineta, Inc. on June 30, 2025. TBS-2025 is planned for a phase 1b/2 trial in relapsed or refractory NPM1-mutated acute myeloid leukemia. The Delta Opioid Receptor technology underlies a set of antibody-drug conjugates the company is developing.
Neither the 10-K nor the 8-K reports trial results for IFx2.0 or TBS-2025, so the efficacy of both is untested in these documents.
The company was formed in Nevada in 2009 under the name Berry Only Inc. It became TuHURA through a reverse merger with Kintara Therapeutics, completed October 18, 2024.
The money
The 10-K shows no revenue in 2025 or 2024. Research and development expense was $20.5 million in 2025, up from $13.3 million in 2024. The net loss was $30.1 million in 2025, compared with $21.7 million in 2024. Cash used in operations was $27.6 million in 2025 and $14.7 million in 2024.
Year-end cash and cash equivalents were $3.6 million for 2025, according to a 10-Q filed August 14, 2026, and $12.7 million for 2024. At June 30, 2026, cash and cash equivalents were $995,977.
The cash position at mid-2026 is less than $1 million. The company's 2025 operating cash use was $27.6 million, so the draw is a small addition to its funding.
What comes next
The filing gives no date for the phase 3 readout and no timetable for the TBS-2025 trial. It lists the company's need for additional capital among its forward-looking topics, and the Parkview revolver is the only financing this 8-K describes. The facility matures April 21, 2031, and the filing gives no repayment schedule before that date.